Fig. 1: Treatment and survival of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). | Blood Cancer Journal

Fig. 1: Treatment and survival of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

From: Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands

Fig. 1

Treatment across lines of therapy for patients with R/R DLBCL (A) and event-free survival (EFS) and overall survival (OS) from start of subsequent treatment shown for the total cohort (B, D, respectively) and per R/R disease subgroup (C, E, respectively). The intensive regimens group consists of high-dose salvage chemotherapy regimens such as R-DHAP, R-VIM, R-DHAP/VIM, R-IGEV, R-GDP, or R-ICE and normally patients with a response continue with auto-SCT. The R-other group contains regimens such as R-PECC or R-bendamustine. The other group contains regimens such as lenalidomide, brentuximab vedotin, pixantrone, selinexor or PECC without rituximab. R-DHAP rituximab, dexamethasone, high-dose cytarabine (Ara-C), cisplatin, R-VIM rituximab, etoposide, ifosfamide, methotrexate, R-IGEV rituximab, ifosfamide, gemcitabine, vinorelbine, R-GDP rituximab, gemcitabine, cisplatin, dexamethasone, R-ICE rituximab, ifosfamide, carboplatin, etoposide, (R-)PECC (rituximab), prednisolone, etoposide, chlorambucil, lomustine, R-bendamustine rituximab, bendamustine.

Back to article page